Transgene presents preclinical results of TG1050, an HBV-targeted immunotherapy, at AASLD 2016 Liver Meeting

information fournie par Boursorama •14/11/2016 à 18:00

Strasbourg, France, November 14, 2016, 6:00 p.m. CET— Transgene (Euronext Paris: TNG), a company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases, today presented a poster on TG1050 preclinical results at the AASLD (American Association for the Study of Liver Diseases) Liver Meeting 2016, Boston (MA). TG1050 is a therapeutic vaccine for the treatment of chronic hepatitis B (or HBV infection).

The abstract published in Hepatology can be downloaded on the AASLD website
(DOI: 10.1002/hep.28800). The poster is available on Transgene’s website.

Poster title: TG1050, an HBV-targeted immunotherapeutics, efficiently decreases HBV viremia and antigenemia in a preclinical model; a meta-analysis and the determination of the involvement of CD4 and CD8 T cells.

The poster shows a meta-analysis of preclinical data obtained with TG1050 in HBV persistent mice and preliminary data on the mode of action of TG1050.